Adjusted Earnings Before Interest Taxes Depreciation and Amortization and IFRS voodoo on Gain on Bios and any "Other Income/Expenses". Interesting to reflect back on the Gross Margin and chart and note the ordinal ranking. Top 4 Gross Margin are also Top 4 for +EBITDA. .Note the colours are not the same, so you'll need to look at the index.
Next patent up is titled “Cannabis extracts and methods of preparing and using the same”, owned by United Cannabis Corp. They’re publicly traded on the OTC Markets under CNAB. The patent has been approved in the USA under US9730911B2 and is set to expire in 2035. The patent is still pending in many countries, including Canada. The patent has already been used by United Cannabis Corp to file a patent infringement claim in Colorado. Starting with the abstract:“The invention relates to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance (BDS) for incorporation in to…
Aphria doesn't include Projected Yield from Bio Assets, nor Harvest KGs.
As we finally start getting "clean" (eg. with no need to back-out 9 month YTD from Annual Reports) Quarterly earnings reports from recently public US MSOs, we can start doing Peer Comparisons and Trend Analysis. And boy howdy, do I have a lot of graphs coming your way. This one is what the implied Breakeven Sales required to evidence a positive Net Operating Profit. As you can see, both Trulieve and CWEB have already achieved +NOP, so they are under 100%. If you remember the North American Gross Margin Peer I hung up early this week... you can see why I am harping on…
Tilray reports in US GAAP, so no Bio Assets.